# BART (NCT02951325)

> Bladder Cancer Adjuvant Radiotherapy Trial

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: postcystectomy muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02951325
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Tata Memorial Centre
- Conditions: Bladder Cancer; Urothelial Carcinoma Bladder
- Interventions: Adjuvant RT
- Enrollment: 153
- Primary outcome: Improvement in loco-regional relapse free survival (LRFS)

## Questions raised in the commentary

_Automated from the 40 newest of 58 indexed sources (Sep 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adjuvant radiotherapy should be used for high-risk disease in current practice
- Whether adjuvant radiotherapy improves overall survival
- How adjuvant radiotherapy can be integrated with contemporary systemic therapy, including immunotherapy

Also discussed: toxicity.

## Indexed commentary on BART so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 46
- Podcasts: 6
- X videos: 4
- YouTube: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bart-nct02951325

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02951325", "email": "<work email>"}; the inbox owner confirms by the emailed link.